A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 535
- Population
- ALL · 50 Years
- Duration
- 2018-10-30 to 2021-07-01
- Intervention
- Brolucizumab; Aflibercept
- Comparator
- Aflibercept
- Outcomes measured
- Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Week 52 — Baseline, week 52; Stable Visual Acuity (VA) or Improvement in VA at Week 52 and Week 104 — Baseline, weeks 52 and 104; Loss in Best-Corrected Visual Acuity (BCVA) of 5 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…; Loss in Best-Corrected Visual Acuity (BCVA) of 10 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…; Loss in Best-Corrected Visual Acuity (BCVA) of 15 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…; Gain in Best-Corrected Visual Acuity (BCVA) of 5 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…; Gain in Best-Corrected Visual Acuity (BCVA) of 10 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…; Gain in Best-Corrected Visual Acuity (BCVA) of 15 Letters or More — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 4…; Change in Central Subfield Thickness (CST) From Baseline — Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48…; Number of Participants With Intraretinal Fluid (IRF) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60,…; Number of Participants With Subretinal Fluid (SRF) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64…; Number of Participants With Sub-Retinal Pigment Epithelium (Sub-RPE) Fluid — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40…; Number of Participants With Fluid-free Status (no IRF, SRF or Sub-RPE Fluid) — Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36,…; Time to First Dry Retina (no IRF or SRF) — Baseline, Up to Week 104 (assessments every 4 weeks); Time to Sustained Dry Retina (no IRF or SRF at ≥ 2 Consecutive Visits) — Baseline, Up to Week 104 (assessments every 4…; Number of Participants With Anti-drug Antibody (ADA) Negative Status — Baseline, weeks 4, 12, 24, 36, 52, 76 and 104; Free Brolucizumab Serum Concentration — pre-dose a baseline, weeks 4, 12, 24, 36, 52, 76 and 104
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.